A global fund intended to turn the commercial value of genetic data into support for nature is facing an early test at the UN biodiversity talks in Armenia: whether a voluntary contribution system can deliver money on a meaningful scale.
On 22 October, the Guardian reported $7,085 deposited against $10,656 committed to the Cali Fund as of 19 October.
Those figures are attributed to that reporting; SMD could not independently retrieve the live totals from the UN financial dashboard. The fund’s own 15 October announcement confirms that Belgian biodiversity-monitoring company E-BIOM became its third corporate contributor.
The central question is larger than the opening balance. Countries have agreed that benefits from using nature’s genetic information should be shared. Building a dependable route from that principle to conservation budgets remains unfinished work.
How nature’s information becomes commercial value
Digital sequence information, usually shortened to DSI, allows researchers to work with genetic information without obtaining a fresh physical specimen. As UNEP explains, online databases hold sequence data from plants, animals and microorganisms, supporting research and commercial development.
This creates a practical mismatch. Information can travel rapidly between laboratories and businesses, while the ecosystems from which it originated still require protection. A product’s development may draw on a distributed body of knowledge rather than one easily identifiable collection expedition.
The Cali Fund seeks to share benefits through a collective financing mechanism. It is not designed to charge every researcher for downloading a sequence. The fund’s COP17 guidance says public database access remains free and open, with benefit-sharing handled separately.
What companies are being asked to contribute
The underlying Convention on Biological Diversity decision sets indicative contributions of 1% of profits or 0.1% of revenue for qualifying commercial users. The size test requires exceeding at least two thresholds, averaged over the preceding three years: US$20 million in assets, US$50 million in sales or US$5 million in profit.
These are guidelines under a voluntary mechanism, not a universal tax already collected from every biotechnology business. The decision invites governments to introduce measures encouraging contributions. It excludes listed-sector businesses that do not directly or indirectly use DSI, and does not expect monetary contributions from public research institutions, universities or public database operators.
E-BIOM provides a small, concrete example of participation. According to the fund, the company analyses environmental DNA—traces organisms leave in water, soil and other surroundings—and has committed to allocating 0.1% of the value of each environmental-DNA service to the fund. That company-specific commitment should not be confused with the general contribution guidelines.
Potential revenue is not a bank balance
A June working paper from LSE’s Grantham Research Institute estimated annual revenue of US$3.6 billion under full participation by eligible firms. Under the researchers’ assumptions about voluntary participation, the estimate fell to US$929 million.
These are modelled scenarios, not pledges or forecasts guaranteed to materialise. The analysis identifies dependence on a relatively small group of large businesses and warns that slow early participation could substantially reduce cumulative receipts.
For readers assessing progress, three numbers answer different questions: potential revenue describes a scenario; commitments describe announced support; deposits describe money received. A fourth question follows—how much reaches recipients and what it achieves. Moving between these measures without identifying them can make a funding announcement appear more substantial than it is.
Who receives the money matters too
The fund’s design directs at least half its resources towards the self-identified needs of Indigenous Peoples and local communities. Its COP17 agenda includes allocation methodology, contribution rates and thresholds, and assessment of the mechanism’s effectiveness. Negotiations run from 19 to 30 October in Yerevan; those agenda items should not be mistaken for completed decisions.
The LSE analysis also shows that allocation choices can substantially change which countries benefit. Raising money and distributing it fairly are separate design problems.
That connects with SMD’s reporting on why conservation coverage alone does not establish that nature is benefiting. Recognition needs to be accompanied by resources, fair governance and evidence of ecological results. A funding mechanism should likewise be judged beyond its headline total.
The useful test after COP17 will be whether clearer arrangements lead to sustained contributions, transparent transfers and support that recipients can use. The Cali Fund has an ambitious purpose. Its credibility will depend on making that chain visible—from businesses benefiting from genetic information to the people and ecosystems sustaining it.
Featured photograph: “Braulio Carrillo National Park 2”, Costa Rica, photographed on 22 May 2013 by MongeNajera. Original photograph via Wikimedia Commons, licensed CC BY-SA 3.0. Illustrative image; it does not depict a Cali Fund project. Web display may resize or crop the photograph; adaptations of the photograph remain under CC BY-SA 3.0.
